Rheumatoid Arthritis Treatment Advances and Developments
  To send this page to a family member or friend, simply fill out the form below. All fields are required.  
  From:
  Name
E-mail
  To:
  Name
E-mail
Submit
Genentech and Biogen Idec are not responsible for the content entered here. We will not use your information for any purpose other than sending an e-mail to the address you have requested. To learn more about our use of your information, please read our Privacy Policy.

System Error


We're sorry, but a system error has occurred.

Thank You

Thank you for visiting www.RISEsupport.com.

The page you requested has been sent to .

Advances in RA Treatment


While there is still no cure for rheumatoid arthritis (RA), great strides have been made in RA research over the last 2 decades. It's important to keep up with these developments and ask your rheumatologist about their potential.

Since the 1980s, disease-modifying antirheumatic drugs (DMARDs) have been the standard among RA treatments because they do more than just treat symptoms. They can actually slow the development of RA.

In the 1990s, a new type of DMARD called biologic DMARDs was introduced. Many of these treatments target a chemical in the immune system called tumor necrosis factor (TNF), which is directly involved in the inflammation of RA. These drugs are known as anti-TNFs (also called TNF inhibitors).

Today, there are other types of biologics that target different parts of the immune system to treat RA. These biologics include a T-cell modulator, an interleukin-1 inhibitor, an interleukin-6 inhibitor, and a targeted B-cell therapy. If you and your rheumatologist are considering a biologic, remember to weigh the potential benefits and risks along with your treatment history.